Michael Milken

Michael Milken
Name	Michael Milken
Birth date	1946-07-04
Birth place	Berkeley, California, U.S.
Occupation	Financier, philanthropist, investor
Alma mater	University of California, Berkeley; University of Pennsylvania (Wharton)

Michael Milken Michael Milken (born July 4, 1946) is an American financier and philanthropist known for transforming corporate finance through innovations in high-yield debt and for his later philanthropic work in medical research and education. He rose to prominence at Drexel Burnham Lambert during the 1970s and 1980s, became a central figure in leveraged buyouts involving figures like Michael Milken contemporaries, and later faced legal challenges culminating in indictment and conviction. After serving his sentence, he became active in funding biomedical research, collaborating with institutions such as UCLA and Johns Hopkins University.

Early life and education

Born in Berkeley, California, Milken grew up in a Jewish family with roots in New Jersey and California. He attended University of California, Berkeley where he studied business and earned undergraduate degrees before enrolling in the Wharton School of the University of Pennsylvania, a division of University of Pennsylvania, where he completed an MBA and a PhD in finance. During his academic formation he studied under faculty associated with capital markets theory and connected with contemporaries who later worked at firms like Lehman Brothers, Goldman Sachs, and Morgan Stanley.

Career at Drexel Burnham Lambert

Milken joined Drexel Burnham Lambert in the early 1970s when the firm was led by figures such as Ira Millstein and later Irwin Jacobs; the firm became a hub for innovative underwriting and trading. At Drexel he rose to head the high‑yield securities group, interacting with executives from RJR Nabisco, Kaiser Aluminum, Texaco, and private equity firms including KKR and Bain Capital. He worked alongside colleagues who became prominent in Wall Street culture, including traders and bankers from Salomon Brothers, Merrill Lynch, and Bear Stearns. Under his leadership Drexel expanded dealings with corporate issuers, investment banks, and institutional investors such as Pension Benefit Guaranty Corporation counterparts and BlackRock-linked asset managers.

Junk bond innovations and finance impact

Milken is widely credited with developing a liquid market for high‑yield debt—commonly called "junk bonds"—which reshaped the corporate finance landscape by enabling leveraged buyouts and restructurings involving companies like Mellon Financial targets and conglomerates such as Gulf+Western. His work connected capital markets participants including Institutional Investor analysts, Moody's Investors Service, and Standard & Poor's ratings committees. The high‑yield market facilitated transactions by private equity firms, influential corporate raiders like Carl Icahn, and management teams in leveraged transactions that intersected with regulatory bodies such as the Securities and Exchange Commission and tax authorities. Critics and supporters debated its role in deals involving US Steel, Pan Am, and other major corporations; defenders cited enhanced access to capital for mid‑market issuers, while opponents pointed to volatility highlighted during episodes involving Black Monday (1987) and other market shocks.

Legal troubles, indictment, and conviction

In the late 1980s Milken and Drexel became focal points of investigations by the United States Department of Justice and the Securities and Exchange Commission into trading practices, insider information, and securities law violations. High‑profile prosecutions involved other financial figures, prosecutors from the Manhattan District Attorney's office, and federal judges such as those from the United States District Court for the Southern District of New York. Milken was indicted on multiple counts including securities fraud and conspiracy; his legal proceedings intersected with testimony from executives at Drexel Burnham Lambert, cooperating witnesses tied to deals involving Revlon and Forstmann Little. He eventually pleaded guilty to securities and reporting violations, received a prison sentence, paid fines, and was barred from the securities industry by regulators including the SEC. The collapse of Drexel in 1990 followed parallel civil and criminal actions, and settlements with creditors and plaintiffs involved firms such as Credit Suisse and Citigroup in later years.

Later career, philanthropy, and advocacy

After his release, Milken pivoted to philanthropy and advocacy, founding or funding organizations that partnered with institutions like UCLA, Johns Hopkins University, Duke University, and Harvard University on medical research initiatives. He established the Milken Institute, which hosts conferences attracting leaders from World Bank, International Monetary Fund, and multinational corporations, and he launched the Prostate Cancer Foundation and initiatives in gene therapy and rare diseases that involved collaborations with National Institutes of Health researchers and biotech firms such as Amgen and Genentech. Milken also supported school reform programs with organizations like KIPP and funded research centers at Cedars-Sinai Medical Center and Mount Sinai Health System. His advocacy extended to criminal‑justice reform, working with policymakers including members of the United States Congress and state governors on sentencing and rehabilitation policies.

Personal life and legacy

Milken has been married and his family life intersected with philanthropic endeavors in education and healthcare, engaging with trustees and boards at institutions like Yale University and Stanford University. His public legacy remains contested: praised by figures in finance and philanthropy for accelerating capital access and supporting medical breakthroughs, and criticized by legal scholars, journalists from outlets such as The New York Times and The Wall Street Journal, and regulators for the conduct that led to his conviction and Drexel's downfall. His work influenced later generations of financiers at firms including Blackstone, Apollo Global Management, and TPG Capital, and his philanthropic network continues to fund research cited in journals like Nature and The Lancet.

Category:American financiers Category:Philanthropists from California